Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder

NCT00326300 is registered in ClinicalTrials.gov with McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. as lead sponsor.

NCT NCT00326300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00326300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder
Lead sponsor
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2006
Completion date
August 31, 2007
Enrollment
560 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder